Literature DB >> 1286979

Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51.

G J Bouma1, P M van der Meer-Prins, F P van Bree, J J van Rood, F H Claas.   

Abstract

We report on the use of europium (Eu) as a suitable nonradioactive alternative for target cell labeling in limiting dilution analysis (LDA) assays set up to determine cytotoxic T-lymphocyte precursor (CTLp) frequencies. A nonradioactive alternative to the commonly used chromium-51 (51Cr) release assay seems desirable because working with radioisotopes has some major disadvantages concerning possible health risks, environmental load, costs of facilities necessary for working with radioisotopes, and shelf life. Some groups have successfully applied the Eu release assay based on detection by time-resolved fluorometry, to tests in which NK- or LAK-cell activity or cytotoxic T-lymphocyte reactions were measured. This led to the investigation whether this method could also be applicable to the more specific determination of CTLp frequencies in LDA assays. After optimal labeling conditions had been established, the sensitivity of the Eu release assay was determined by performing several LDA assays in which the target cells were labeled with either Eu or radioactive 51Cr. When CTLp frequencies were compared, it was shown that the Eu release assay is at least as sensitive and specific as the 51Cr release assay. Moreover, although the labeling procedure takes longer, sample processing is much faster: only 1 second per sample. The fact that the Eu release assay is not radioactive enables the assay to be performed at any laboratory and even--because the frequency of CTLps may have implications for organ graft survival and for donor selection in bone marrow transplantation--to do so on a routine basis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1286979     DOI: 10.1016/0198-8859(92)90015-f

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.

Authors:  V A L Huurman; C R van der Torren; P Gillard; R Hilbrands; E P M W van der Meer-Prins; G Duinkerken; F K Gorus; F H J Claas; B Keymeulen; D L Roelen; D G Pipeleers; B O Roep
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Identification of Donor Origin and Condition of Transplanted Islets In Situ in the Liver of a Type 1 Diabetic Recipient.

Authors:  Cornelis R van der Torren; Jessica S Suwandi; DaHae Lee; Ernst-Jan T Van't Wout; Gaby Duinkerken; Godelieve Swings; Arend Mulder; Frans H J Claas; Zhidong Ling; Pieter Gillard; Bart Keymeulen; Peter In't Veld; Bart O Roep
Journal:  Cell Transplant       Date:  2016-10-10       Impact factor: 4.064

3.  T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.

Authors:  W M Smit; M Rijnbeek; C A van Bergen; W E Fibbe; R Willemze; J H Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

4.  Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.

Authors:  D L Roelen; V A L Huurman; R Hilbrands; P Gillard; G Duinkerken; P W M van der Meer-Prins; M F J Versteeg-van der Voort Maarschalk; C Mathieu; B Keymeulen; D G Pipeleers; B O Roep; F H J Claas
Journal:  Clin Exp Immunol       Date:  2009-01-21       Impact factor: 4.330

5.  Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

Authors:  M P Vierboom; H W Nijman; R Offringa; E I van der Voort; T van Hall; L van den Broek; G J Fleuren; P Kenemans; W M Kast; C J Melief
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

6.  Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.

Authors:  Volkert A L Huurman; Robert Hilbrands; Gabriëlle G M Pinkse; Pieter Gillard; Gaby Duinkerken; Pieter van de Linde; Petronella M W van der Meer-Prins; Minke F J Versteeg-van der Voort Maarschalk; Koen Verbeeck; Behrooz Z Alizadeh; Chantal Mathieu; Frans K Gorus; Dave L Roelen; Frans H J Claas; Bart Keymeulen; Daniel G Pipeleers; Bart O Roep
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.